Tanja Obradovic: Are we to see a major improvement in treatment options for glioblastoma patients?
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:
“Are we to see a major improvement in treatment options for glioblastoma patients after decades of development still far from delivering at the bedside? Chances may be increasing considering latest news on novel agent LP-184 that strengthens hope of clinical activity.
Lantern Pharma Inc. (Nasdaq: LTRN), an innovative Biotech that utilizes power of AI in drug development announced second Fast Track designation by FDA for LP-184 that follows one in glioblastoma and this time for patients with triple negative breast cancer (TNBC) via sensitization to checkpoint inhibitors.
LP-184, is a small molecule acylfulvene prodrug metabolized to an active compound by the oxidoreductase activity of enzyme prostaglandin reductase 1 (PTGR1), which is frequently elevated in multiple solid tumor types.
Tumors deficient in a spectrum of DNA damage repair (DDR) pathway genes show increased susceptibility to LP-184 and ongoing Phase 1A clinical trial (NCT05933265) across multiple solid tumor indications is informing about promising benefit in at least glioblastoma and TNBC.
Indeed outstanding success by Lantern team toward potential to rapidly reach patients in a great need.”
More posts featuring Tanja Obradovic.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023